Jon Alberdi joins industry leaders to discuss the maturity and future of cell and gene therapy at ARM’s Meeting on the Med 2026

What are recent breakthroughs telling us about the maturity of the cell and gene therapy (CGT) field?

This question is explored in the latest episode of Roving Reporter, produced by The Medicine Maker in partnership with IBTV and recorded live at ARM’s Meeting on the Med 2026 in Rome.

The episode explores how recent clinical, regulatory, and commercial achievements are driving cell and gene therapy into a new phase of growth and maturity. Bringing together leading voices from across the sector, the discussion examines both the significant progress achieved to date and the challenges that still need to be addressed to expand patient access to these innovative therapies.

Among the featured speakers is Jon Alberdi, CEO of VIVEbiotech, who shares his perspective on the growing maturity of the sector and the opportunities this evolution creates for the future of advanced therapies. During the discussion, Alberdi highlights how the increasing clinical validation of gene therapies across a broader range of indications, together with emerging regulatory and commercial milestones, reflects the sustained progress of an industry that continues to expand its potential impact on patients’ lives.

The conversation also emphasizes how scientific innovation, evolving regulatory frameworks, and increasing industrial expertise are helping to build a stronger ecosystem capable of translating advanced therapies from research into routine clinical practice.

As a CDMO specialized in lentiviral vectors for both ex vivo and in vivo gene therapies, VIVEbiotech remains committed to developing and manufacturing solutions that help accelerate the delivery of transformative treatments to a greater number of patients worldwide, supporting partners in advancing the next generation of cell and gene therapies.

The full interview is available here.